Paxil OS GMP Concerns Resolved By Year-End, GSK Says After Warning Letter
Executive Summary
GlaxoSmithKline expects to resolve GMP issues related to production of Paxil oral suspension at its Certenejas Cidra, Puerto Rico facility by the end of the month, the company said